Oestrous cycle and pregnancy alter the reactivity of the rat uterine vasculature.
Isolated uterine vascular beds from virgin and pregnant rats were used to assess vascular reactivity and the ability of nitric oxide (NO), prostanoids and endothelium-derived hyperpolarizing factor (EDHF) to modulate these responses. One uterine horn from female rats in each oestrous cycle day and gestation day 17 was removed and perfused with physiological saline solution. Tone was induced with cirazoline (1 micromol/l), and concentration-response curves to acetylcholine (ACh) generated. Responsiveness to ACh was tested in the presence of N-nitro-L-arginine (L-NA), ibuprofen (IBU) and tetrabutylammonium (TBA), to inhibit NO synthase, cyclo-oxygenase and K+ channels respectively. Cirazoline-induced tone was smaller in the pregnant compared with the proestrous group. Sensitivity to ACh was cycle day and pregnancy dependent with pregnant > dioestrous day-1 > dioestrous day-2 > proestrous and oestrous. L-NA shifted the curve to the right in all groups except dioestrous day-1. IBU inhibited the ACh response in the pregnant group only. TBA virtually abolished the response in all groups. These results suggest that in the uterine vascular bed from pregnant rats, EDHF, along with NO and a dilator prostanoid mediate ACh-induced dilatation. In contrast, in the dioestrous day-1 group, only EDHF seems to be released by ACh in this vascular bed. In the oestrous, dioestrous day-2 and proestrous groups, ACh releases both EDHF and NO.
Dalle Lucca
J J
JJ
Center for Applied Microcirculatory Research, Health Sciences Center, A1115, University of Louisville School of Medicine, Louisville, KY 40292, USA.
Adeagbo
A S
AS
Alsip
N L
NL
D000109:Acetylcholine / Q000494:pharmacology; D000322:Adrenergic Agonists / Q000494:pharmacology; D000818:Animals; D001685:Biological Factors / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004031:Diestrus; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004971:Estrus; D005260:Female; D005865:Gestational Age; D007052:Ibuprofen / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D019335:Nitroarginine / Q000494:pharmacology; D026902:Potassium Channel Blockers; D011247:Pregnancy; D011359:Proestrus; D011453:Prostaglandins / Q000502:physiology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014599:Uterus / Q000098:blood supply* / Q000187:drug effects
D000322:Adrenergic Agonists; D001685:Biological Factors; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D007093:Imidazoles; D026902:Potassium Channel Blockers; D011453:Prostaglandins; D000644:Quaternary Ammonium Compounds; C067410:endothelium-dependent hyperpolarization factor; D019335:Nitroarginine; D009569:Nitric Oxide; C009405:tetrabutylammonium; D019001:Nitric Oxide Synthase; D000109:Acetylcholine; C014282:cirazoline; D007052:Ibuprofen